These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
367 related articles for article (PubMed ID: 24326846)
1. Increased expression of biological markers as potential therapeutic targets in Saudi women with triple-negative breast cancer. Sayed-Ahmed MM; Hafez MM; Al-Shabanah OA; Al-Rejaie SS; Aleisa AM; Al-Yahya AA; Alsheikh A; Al Diab AI; Al-Akeely MH Tumori; 2013; 99(4):545-54. PubMed ID: 24326846 [TBL] [Abstract][Full Text] [Related]
2. Increased hypermethylation of glutathione S-transferase P1, DNA-binding protein inhibitor, death associated protein kinase and paired box protein-5 genes in triple-negative breast cancer Saudi females. Hafez MM; Al-Shabanah OA; Al-Rejaie SS; Al-Harbi NO; Hassan ZK; Alsheikh A; Al Theyab AI; Aldelemy ML; Sayed-Ahmed MM Asian Pac J Cancer Prev; 2015; 16(2):541-9. PubMed ID: 25684485 [TBL] [Abstract][Full Text] [Related]
3. Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Bouchalova K; Cizkova M; Cwiertka K; Trojanec R; Hajduch M Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):13-7. PubMed ID: 19365520 [TBL] [Abstract][Full Text] [Related]
4. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer. Li M; Li A; Zhou S; Lv H; Yang W J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840 [TBL] [Abstract][Full Text] [Related]
5. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt. Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605 [TBL] [Abstract][Full Text] [Related]
6. Expression of HIF-1α and Markers of Angiogenesis Are Not Significantly Different in Triple Negative Breast Cancer Compared to Other Breast Cancer Molecular Subtypes: Implications for Future Therapy. Yehia L; Boulos F; Jabbour M; Mahfoud Z; Fakhruddin N; El-Sabban M PLoS One; 2015; 10(6):e0129356. PubMed ID: 26046764 [TBL] [Abstract][Full Text] [Related]
7. High expression of FUSE binding protein 1 in breast cancer stimulates cell proliferation and diminishes drug sensitivity. Liu W; Xiong X; Chen W; Li X; Hua X; Liu Z; Zhang Z Int J Oncol; 2020 Aug; 57(2):488-499. PubMed ID: 32626933 [TBL] [Abstract][Full Text] [Related]
8. Advances in Therapeutic Approaches for Triple-Negative Breast Cancer. Mahtani R; Kittaneh M; Kalinsky K; Mamounas E; Badve S; Vogel C; Lower E; Schwartzberg L; Pegram M; Clin Breast Cancer; 2021 Oct; 21(5):383-390. PubMed ID: 33781662 [TBL] [Abstract][Full Text] [Related]
9. Triple Negative Breast Cancer: A Tale of Two Decades. Ali AM; Ansari JAK; El-Aziz NMA; Abozeed WN; Warith AMA; Alsaleh K; Nabholtz JM Anticancer Agents Med Chem; 2017; 17(4):491-499. PubMed ID: 27456662 [TBL] [Abstract][Full Text] [Related]
10. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors. Park Y; Moriyama A; Kitahara T; Yoshida Y; Urita T; Kato R Anticancer Agents Med Chem; 2012 Jul; 12(6):672-7. PubMed ID: 22263793 [TBL] [Abstract][Full Text] [Related]
11. Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer. Boerner JL; Nechiporchik N; Mueller KL; Polin L; Heilbrun L; Boerner SA; Zoratti GL; Stark K; LoRusso PM; Burger A PLoS One; 2015; 10(3):e0119614. PubMed ID: 25774912 [TBL] [Abstract][Full Text] [Related]
12. Triple-negative breast cancer: advancements in characterization and treatment approach. Hurvitz S; Mead M Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831 [TBL] [Abstract][Full Text] [Related]
13. miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer. Tan X; Peng J; Fu Y; An S; Rezaei K; Tabbara S; Teal CB; Man YG; Brem RF; Fu SW Breast Cancer Res; 2014 Sep; 16(5):435. PubMed ID: 25228385 [TBL] [Abstract][Full Text] [Related]
14. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells. Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187 [TBL] [Abstract][Full Text] [Related]
15. Biology and Management of Patients With Triple-Negative Breast Cancer. Sharma P Oncologist; 2016 Sep; 21(9):1050-62. PubMed ID: 27401886 [TBL] [Abstract][Full Text] [Related]
16. Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. Jovanović B; Sheng Q; Seitz RS; Lawrence KD; Morris SW; Thomas LR; Hout DR; Schweitzer BL; Guo Y; Pietenpol JA; Lehmann BD BMC Cancer; 2017 Apr; 17(1):241. PubMed ID: 28376728 [TBL] [Abstract][Full Text] [Related]
17. Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer. Lumachi F; Chiara GB; Foltran L; Basso SM Cancer Genomics Proteomics; 2015; 12(6):385-90. PubMed ID: 26543084 [TBL] [Abstract][Full Text] [Related]
18. BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer. Okuma HS; Yonemori K Adv Exp Med Biol; 2017; 1026():271-286. PubMed ID: 29282689 [TBL] [Abstract][Full Text] [Related]
19. Triple-Negative Breast Cancer in Ghanaian Women: The Korle Bu Teaching Hospital Experience. Der EM; Gyasi RK; Tettey Y; Edusei L; Bayor MT; Jiagge E; Gyakobo M; Merajver SD; Newman LA Breast J; 2015; 21(6):627-33. PubMed ID: 26547900 [TBL] [Abstract][Full Text] [Related]
20. Allelic imbalance at the HER2/TOP2A locus in breast cancer. Huijsmans CJ; van den Brule AJ; Rigter H; Poodt J; van der Linden JC; Savelkoul PH; Hilbink M; Hermans MH Diagn Pathol; 2015 May; 10():56. PubMed ID: 26022247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]